The role of positron emission tomography imaging in movement disorders

Neuroimaging Clinics of North America

Volumn 13, Issue 4, 2003, Pages 791-803

  Bohnen, Nicolaas I ^a   Frey, Kirk A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORODEOXYGLUCOSE F 18; LIGAND;

BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN REGION; CORTICOBASAL DEGENERATION; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG RESPONSE; DYSTONIA; ESSENTIAL TREMOR; FUNCTIONAL ASSESSMENT; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; IMAGING SYSTEM; MOTOR DYSFUNCTION; NERVE TRACT; NEUROCHEMISTRY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; STRIATONIGRAL DEGENERATION; SYMPTOMATOLOGY; TIC;

EID: 0344845191     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5149(03)00096-0     Document Type: Review

References (88)

1. Brooks DJ. Imaging basal ganglia function. J Anat 2000;196:543-54.
2. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-81.
3. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-8.
4. 18F]fluoro-dopa, an analogue of dopa, and its use in direct measurement of storage, degeneration, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 1978;75:464-7.
5. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-31.
6. 123lb-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98.
7. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-84.
8. 3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995;68:955-62.
9. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-55.
10. 18F]dopa-PET study. Brain 1999;122:1637-50.
11. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
12. Antonini A, Vontobel P, Psylla M, Günther I, Maguire RP, Missimer J, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995;52:1183-90.
13. 123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-67.
14. 123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17:518-23.
15. 11C]raclopride displacement and PET. Neurology 1996;46:1430-6.
16. Kish SJ, Shannak K, Homykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-80.
17. Bemheimer H, Birkmayer W, Homykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55.
18. Bohnen N, Meyer P, Albin RL, Minoshima S, Wernette K, Koeppe RA, et al. Clinical correlates of striatal (+)-[C-11]DTBZ binding to VMAT2 in Parkinson's disease. J Nucl Med 1998;39(Suppl):15P.
19. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-83.
20. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-64.
21. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-9.
22. Frey KA, Albin RL, Koeppe RA, Kuhl DE, Kilbourn ME. Assessment of Parkinson's disease progression with VMAT2 PET. J Nucl Med 2000;41(Suppl): 137P-8P.
23. Brucke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000;247(Suppl 4):2-7.
24. 11C] raclopride. Mov Disord 1997;12:33-8.
25. Wolfson LI, Leenders KL, Brown LL, Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology 1985;35:1399-405.
26. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity. J Nucl Med 1997;38:797-802.
27. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996;153:41-9.
28. Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, Nelson MJ, et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996;37:1133-41.
29. Brooks DJ, Frackowiak RSJ. PET and movement disorders. J Neurol Neurosurg Psychiatry 1989; Suppl(June):68-77.
30. 18F]fluorodopa positron emission tomographic studies. Mov Dis 1990;5:203-13.
31. Antonini A, Moeller JR, Nakamura T, Spetsieris P, Dhawan V, Eidelberg D. The metabolic anatomy of tremor in Parkinson's disease. Neurology 1998;51:803-10.
32. Dethy S, Van Blercom N, Damhaut P, Wikler D, Hildebrand J, Goldman S. Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism. Mov Disord 1998;13:275-80.
33. Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992;32:151-61.
34. Ceballos-Baumann AO, Boecker H, Bartenstein P, von Falkenhayn I, Riescher H, Conrad B, et al. A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch Neurol 1999;56:997-1003.
35. Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain 2001;124:1601-9.
36. Feamley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
37. 18F-dopa and positron emission tomography. Neurology 1992;42:1894-900.
38. 18F-Dopa positron emission tomography study. Ann Neurol 1997;41:222-9.
39. Quinn N. Parkinsonism-recognition and differential diagnosis. BMJ 1995;310:447-52.
40. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brainstem, basal ganglia, and cerebellum, with vertical gaze and pseudobulbar palsy. Arch Neurol 1964;10:333-59.
41. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994;117:235-43.
42. Feany MB, Ksiezak-Reding H, Liu WK, Vincent I, Yen SH, Dickson DW. Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: differentiation from progressive supranuclear palsy. Acta Neuropathol (Berl) 1995;90:37-43.
43. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-92.
44. 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994;57:1047-56.
45. 18F-FDG. Ann Nucl Med 1997;11:251-7.
46. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994;36:166-75.
47. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988;24:399-406.
48. D'Antona R, Baron JC, Samson Y, Serdaru M, Viader F, Agid Y, et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985;108:785-99.
49. Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic landscape of corticobasal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;54:856-62.
50. Garraux G, Salmon E, Peigneux P, Kreisler A, Degueldre C, Lemaire C, et al. Voxel-based distribution of metabolic impairment in corticobasal degeneration. Mov Disord 2000;15:894-904.
51. Augood SJ, Faull RLM, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997;42:215-21.
52. Ginovart N, Lundin A, Farsde L, Halldin C, Bäckman L, Swahn C-G, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120:503-14.
53. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington's disease progression. PET and clinical observations. Brain 1999;122:2353-63.
54. Leenders KL, Frackowiak RSJ, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Dis 1986;1:69-77.
55. Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology 2000;54:1753-9.
56. 18FDG and computed tomographic scan. Ann Neurol 1982;12:425-34.
57. Maziotta JH, Phelps ME, Pahl JJ, Huang S-C, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987;316:357-62.
58. Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 2001;42:1591-5.
59. Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 2002;159:1329-36.
60. Turjanski N, Sawle GV, Playford ED, Weeks R, Lammertsma AA, Lees AJ, et al. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatry 1994;57:688-92.
61. Ernst M, Zametkin AJ, Jons PH, Matochik JA, Pascualvaca D, Cohen RM. High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1999;38:86-94.
62. 123I]b-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-61.
63. Brooks DJ, Turjanski N, Sawle GV, Playford ED, Lees AJ. PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. Adv Neurol 1992;58:227-31.
64. George MS, Robertson MM, Costa DC, Ell PJ, Trimble MR, Pilowsky L, et al. Dopamine receptor availability in Tourette's syndrome. Psychiatry Res 1994;55:193-203.
65. Wolf SS, Jones DW, Knable MB, Gorey JG, Lee KS, Hyde TM, et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 1996;273:1225-7.
66. Jeffries KJ, Schooler C, Schoenbach C, Herscovitch P, Chase TN, Braun AR. The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology 2002;27:92-104.
67. Vidailhet M, Dupel C, Lehericy S, Remy P, Dormont D, Serdaru M, et al. Dopaminergic dysfunction in midbrain dystonia: anatomoclinical study using 3-dimensional magnetic resonance imaging and fluorodopa F 18 positron emission tomography. Arch Neurol 1999;56:982-9.
68. 123I] beta-CIT. Mov Disord 1998;13:319-23.
69. 18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 1997;17:843-50.
70. Snow BJ, Nygaard TG, Takahashi H, Calne DB. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol 1993;1993:733-8.
71. Calne DB, de la Fuente-Fernandez R, Kishore A. Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. J Neural Transm Suppl 1997;50:47-52.
72. 11C]-raclopride and positron-emission tomography. Neurology 1998;50:1028-32.
73. Perlmutter JS, Raichle ME. Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. Ann Neurol 1984;15:228-33.
74. Tempel LW, Perlmutter JS. Abnormal vibration-induced cerebral blood flow responses in idiopathic dystonia. Brain 1990;113:691-707.
75. Feiwell RJ, Black KJ, McGee-Minnich LA, Snyder AZ, MacLeod AM, Perlmutter JS. Diminished regional cerebral blood flow response to vibration in patients with blepharospasm. Neurology 1999;52:291-7.
76. Ibanez V, Sadato N, Karp B, Deiber MP, Hallett M. Deficient activation of the motor cortical network in patients with writer's cramp. Neurology 1999;53:96-105.
77. Ceballos-Baumann AO, Passingham RE, Warner T, Playford ED, Marsden CD, Brooks DJ. Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia. Ann Neurol 1995;37:363-72.
78. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Nakamura T, Dhawan V, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 1998;44:303-12.
79. Kumar R, Dagher A, Hutchison WD, Lang AE, Lozano AM. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. Neurology 1999;53:871-4.
80. Rajput AH, Moghal S, Rajput A. Parkinson's disease and essential tremor. Neurology 1994;44:778.
81. Rajput AH, Rozdilsky B, Ang L, Rajput A. Significance of parkinsonian manifestations in essential tremor. Can J Neurol Sci 1993;20:114-7.
82. Brooks DJ, Playford ED, Ibanez V, Sawle GV, Thompson PD, Findley LJ, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system. Neurology 1992;42:1554-60.
83. Frey KA, Bohnen N, Meyer P, Elmer L, Albin RL, Koeppe RA, et al. (+)-[C-11]DTBZ PET imaging of presynaptic monoaminergic vesicles in isolated postural tremor. J Nucl Med 1998;39(Suppl):210P.
84. 123I]-FP-CIT study group. Mov Disord 2000;15:503-10.
85. 123I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology 1999;52:1422-6.
86. Hallett M, Dubinsky RM. Glucose metabolism in the brain of patients with essential tremor. J Neurol Sci 1993;114:45-8.
87. Colebatch JG, Findley LJ, Frackowiak RS, Marsden CD, Brooks DJ. Preliminary report: activation of the cerebellum in essential tremor. Lancet 1990;336:1028-30.
88. Wills AJ, Jenkins IH, Thompson PD, Findley LJ, Brooks DJ. A positron emission tomography study of cerebral activation associated with essential and writing tremor. Arch Neurol 1995;52:299-305.